Kornimate/medical-research-clean huggingface dataset:
exploring the optimal concentration of lidocaine test dose for labor analgesia

Conditions: Labor Pain

Summary: this study aims to compare the analgesia effects and side effects of different concentrations of test dose lidocaine (1.5% lidocaine 3 ml, 1.0% lidocaine 5 ml, 0.5% lidocaine 10 ml) in labor analgesia, so as to provide a scientific basis for the clinic al practice of labor analgesia.

epidural analgesia is the most effective and widely used analgesic method for relieving labor pain in clinical practice. however, inadvertent insertion of an epidural catheter into a blood vessel or subarachnoid space may result in local anesthesia or total spinal anesthesia, which can be life-threatening. therefore, a low-concentration, low-volume dose of local anesthetic is usually injected as a test dose before injecting a large dose of local anesthetic through the epidural catheter to ensure that the catheter is within the epidural space. at present, the guidelines recommend 3 ml of 1.5% lidocaine as the test dose, but in clinical practice and the study of chen et al., it was found that the test dose of 1.5% lidocaine 3ml still has a high incidence of lower limb motor block of 57.1%, which affects maternal activity and labor progression. in addition, liu henry et al. found that the incidence of 0.5% lidocaine 10 ml test dose-induced motor block was 0%, and the analgesic effect could be quickly achieved. therefore, it is uncertain which concentration of lidocaine has the fastest onset of analgesia and the fewest side effects in labor analgesia. therefore, this study aims to compare the effects of different concentrations of lidocaine (1.5% lidocaine 3 ml, 1.0% lidocaine 5 ml, 0.5% lidocaine 10 ml) in labor analgesia, so as to provide a scientific basis for the clinical practice of labor analgesia.

Eligibility criteria:
inclusion criteria: 1. singleton primipara 2. aged 20-40 years 3. pre-assessed as eligible for vaginal delivery 4. height between 155-170 cm, bmi between 18.5-35 kg/m² 5. cervical dilation between 2-6 cm 6. no significant history of cardiopulmonary disease 7. no history of surgical trauma 8. american society of anesthesiologists (asa) grades i-iii 9. patients are willing to participate and be able to understand and sign an informed consent form exclusion criteria: 1. contraindications for spinal anesthesia, such as coagulopathy or ongoing anticoagulant therapy, infection at the puncture site, bacteremia, epidural abscess, increased intracranial pressure, severe hypovolemia 2. physical or mental disabilities, such as scoliosis and depression, alcohol or drug abuse 3. major organ diseases, such as hyperthyroidism, cardiopulmonary diseases, diabetes treated with insulin, and neuromuscular diseases 4. numerical pain rating scale (nprs) \< 5 5. refusal to participate in the study
midurethral synthetic tape with tension control mechanism versus midurethral free tape

Conditions: Urinary Stress Incontinence

Summary: this is a prospective, comparative randomized controled trial. the general purposes of this study is to compare the efficacy and safety of midurethral synthetic tape with tension control mechanism and conventional midurethral tension free tape as surgical treatment for female urinary stress incontinence.


Eligibility criteria:
inclusion criteria: women suffering from stress urinary incontinence, mixed urinary incontinence with prevalence stress urinary incontinence exclusion criteria: * pregnancy * women with neurogenic bladder dysfunction * recurrent stress urinary incontinence * woman with history of pelvic surgery * mixed urinary incontinence with prevalence urgency urinary incontinence * women who suffer from advanced pop (pop-quantification system (pop-q) stage more than 2) * women with acute urinary tract infection * women with bladder outlet obstruction * women who are not able to give informed consent or participate with this randomized research study for any other reason

Keywords: stress urinary incontinence midurethral tension free tape patient reported outcome bladder outlet obstruction complications tension control mechanism
lcar-m61s and lcar-m61d in treatment of relapsed/refractory multiple myeloma

Conditions: Relapsed/Refractory Multiple Myeloma

Summary: a prospective, two-cohort, open-label dose-exploration and expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor efficacy characteristics of lcar-m61s and lcar-m61d in patients with relapsed/refractory multiple myeloma.

this study was a prospective, two-cohort, open-label clinical study to evaluate the safety, tolerability, pharmacokinetics, and antitumor efficacy characteristics of lcar-m61s and lcar-m61d in patients with relapsed/refractory multiple myeloma. all subjects who meet the eligibility criteria will receive intravenous injection of lcar-m61s or lcar-m61d cell injection. the study will include the following sequential phases: screening, apheresis, pre-treatment (lymphodepleting chemotherapy), treatment, and follow-up.

Eligibility criteria:
inclusion criteria: * subjects voluntarily participate in clinical research; * age ≥18 years old; * eastern cooperative oncology group (ecog) score 0-2; * examination evidence of initial diagnosis of mm according to imwg diagnostic criteria; * measurable lesions were present; * subjects have received at least three previous lines of multiple myeloma therapy, each with at least one complete therapy cycle, unless the best response to the therapeutic regimen was documented as disease progression (pd confirmed according to imwg criteria); * expected survival ≥3 months; * clinical laboratory values in the screening period meet criteria; exclusion criteria: * received previous therapy targeting gprc5d and/or cd19 targets; * prior antineoplastic therapy and meet exclusion criteria (before apheresis); * subjects had waldenstrom macroglobulinemia, poems syndrome, or primary al amyloidosis at the time of screening. * subjects who were positive for any of hbsag, hbv dna, hcv-ab, hcv rna, and hiv-ab; * life-threatening allergic reactions, hypersensitivity reactions, or intolerance to car-t cell formulations or their excipients, including dmso, are known. * serious underlying diseases were present; * female subjects who were pregnant, breastfeeding, or planning to become pregnant while participating in this study or within 1 year of receiving study treatment. * also enrolled in other clinical studies.

Keywords: multiple myeloma relapsed/refractory multiple myeloma
endometriosis robotic assisted surgery

Conditions: Endometriosis

Summary: the purpose of this study is to compare the robot-assisted approach with the laparoscopic approach in terms of reducing the rates of intraoperative and postoperative complications in patients undergoing total hysterectomy for die and adenomyosis without digestive tract involvement.

the endo-ras trial aims to evaluate the safety and effectiveness of robot-assisted laparoscopy compared to conventional laparoscopy for hysterectomy in patients with deep infiltrating endometriosis and adenomyosis without digestive tract involvement, as verified by magnetic resonance imaging and classified using both the enzian and deep pelvic endometriosis index classifications. these classifications are used to evaluate deep infiltrating endometriosis and reproducibly predict the occurrence of postoperative complications. eligible patients will be recruited from the gynecological surgery department after meeting the inclusion and non-inclusion criteria and signed informed consent forms. participants will then be randomly assigned to receive either robot-assisted total laparoscopic hysterectomy or total laparoscopic hysterectomy. the endo-ras trial is a multicenter, randomized, controlled, and open-label study. eligible patients will be randomized into two parallel groups.

Eligibility criteria:
inclusion criteria: * ≥ 18 years of age. * diagnosed adenomyosis, either internal or external (magnetic resonance imaging) per the enzian and dpei classifications. * diagnosed deep infiltrating endometriosis per the enzian and dpei classifications, without the involvement of the digestive tract. * failure of first- and second-line medical treatment. * eligibility for total hysterectomy with complete removal of endometriosis lesions. * participants covered by entitled to social security. * all participants must provide written informed consent before undergoing the surgical procedure. exclusion criteria: * digestive tract involvement. * adenomyosis only. * contraindications to surgery. * participants who are under guardianship, curatorship, or deprivation of liberty.
endoscopic ultrasound-guided celiac plexus neurolysis (eus-cpn)with alcohol in unresectable pancreatic cancer: a pilot study

Conditions: Pancreatic Cancer

Summary: the purpose of this study is to obtain preliminary safety and efficacy data after endoscopic ultrasound-guided celiac plexus neurolysis (eus-cpn) in patients with locally advanced or unresectable pancreatic adenocarcinoma. hypotheses: 1. increased amounts of alcohol used in eus-cpn is safe and more efficacious in improving pain relief in patients with locally advanced or unresectable pancreatic adenocarcinoma. 2. effective pain relief obtained from eus-cpn will be related to better quality of life (qol)


Eligibility criteria:
inclusion criteria: * a total of 20 consecutive subjects with locally advanced or unresectable pancreatic adenocarcinoma (stage ii to iv) with pain (abdominal and/or back). subjects with known or suspected unresectable pancreatic adenocarcinoma will be recruited for this study, as a diagnosis of unresectable pancreatic adenocarcinoma is often made during the endoscopic ultrasound (eus) procedure. * subjects must have documented disease by computed tomography (ct), endoscopic retrograde cholangio-pancreatography (ercp), or eus. * subjects undergoing eus for pancreatic cancer staging. * subjects undergoing pancreatic cancer surgery are eligible for study entry beginning 5 days after the operation if they have not had an intraoperative celiac plexus neurolysis. * no evidence of dementia or altered mental status that would prohibit the giving and understanding of informed consent, and no evidence of psychiatric risk that would preclude adequate compliance with this protocol. subjects must not have a coagulopathy (platelet \ 1.5, or bleeding disorder, or on blood thinners) subjects with platelets below 50,000 will not be eligible to participate in this study due to the risk of bleeding. patients will be asked to discontinue use of non-steroidals for 5 days prior to the procedure. patients on plavix will be asked to discontinue use for 7 days prior to the procedure if they are clinically able to do so. patients on coumadin or lovenox will also need to discontinue use prior to the procedure, but decisions regarding their management will be made on an individual basis as per our usual standards of care. * subjects must provide signed written informed consent. * a baseline pain score is not required, however, subjects must be having pain that is requiring a stable dose of pain medication for control of pain. exclusion criteria: * subjects will be excluded if they have undergone a celiac plexus neurolysis (endoscopic, percutaneous, or surgical). * presence of an implanted epidural or intrathecal analgesic therapy. subjects with psychiatric illness that affects their ability to assess quality of life or compliance with the protocol. * subjects with uncorrectable coagulopathy * subjects with an allergy to bupivacaine or alcohol. * presence of an aneurysm in the abdominal aorta, celiac trunk, or superior mesenteric artery.
modified hook wiring technique for greater tuberosity fractures, a prospective study

Conditions: Greater Tuberosity Fractures

Summary: the purpose of this study is to assess functional and radiological outcome of open reduction and internal fixation of isolated displaced greater tuberosity fractures (more than 5mm displacement) in adults advocating modified hook wiring with a follow-up period of one year.

after being informed about the study and potential risks, all enrolled cases giving informed consent will undergo fixation of their fractured greater tuberosity, then physiotherapy. patients will be followed up till full union, clinical and radiological follow up for at least one year utilizing approved clinical scores and radiological criteria for healing. any complication will be recorded.

Eligibility criteria:
inclusion criteria: patients presented and admitted at mansoura trauma, emergency hospital affiliated to mansoura university, with acute isolated displaced gt fractures ( more than 5mm displacement), with/without glenohumeral dislocations, with age between 18years to 50 years. exclusion criteria: 1. skeletally immature patients (less than 18 years), age more than 50 years. 2. open and pathological fractures 3. associated proximal humeral fractures 4. history of previous gh dislocations 5. history of previous shoulder injuries or surgeries
dipyridamole to prevent coronavirus exacerbation of respiratory status (dicer) in covid-19

Conditions: COVID; Corona Virus Infection; Covid-19; SARS-CoV-2 Infection

Summary: the most severe manifestations of covid-19 include respiratory failure, coagulation problems, and death. inflammation and blood clotting are believed to play an important role in these manifestations. research in humans has shown that dipyridamole can reduce blood clotting. this research study is being conducted to learn whether 14 days of treatment with dipyridamole will reduce excessive blood clotting in covid-19. this study will enroll participants with confirmed coronavirus (sars-cov)-2 infection that are admitted. eligible participants will be randomized to receive dipyridamole or placebo for 14 days in the hospital. in addition, data will be collected from the medical record, and there will also be blood draws during the hospitalization.


Eligibility criteria:
inclusion criteria: * willing and able to provide informed consent prior to performing study procedures unless they have a legally authorized representative (lar) * confirmed coronavirus (sars-cov-2) infection * currently hospitalized or anticipated hospitalization requiring supplemental oxygen exclusion criteria: * in the opinion of at least two investigators, unlikely to survive for \>48 hours from screening * concurrent enrollment in a clinical trial with a cytokine inhibitor (targeting interleukin-6 (il-6), interleukin-6 receptor (il-6r), il-1, or janus kinase). use of remdesivir is permitted. * currently on invasive mechanical ventilation. * hypotension defined as systolic blood pressure \< 90 mmhg on two sequential readings at least 4 hours apart * pregnant or breastfeeding * concurrent dual antithrombotic therapy (aspirin or p2y12 inhibitor plus anticoagulation to treat deep venous thrombosis or pulmonary embolism (single antiplatelet or anticoagulant agent at prophylaxis or therapeutic dose is permitted) * aspartate aminotransferase (ast) or alanine aminotransferase (alt) greater than 5 times upper limit of normal, hemoglobin \< 8 grams per deciliter (g/dl), or platelets \<50,000 per cubic millimeter (mm3) * history of recent major bleeding, defined in accordance with the criteria of the international society on thrombosis and hemostasis (isth). * any physical examination findings and/or history of any illness that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the patient by their participation in the study

Keywords: oxygen
goal2quit + nrt sampling

Conditions: Cigarette Smoking; Smoking Cessation; Depression

Summary: the goal of this work is to develop, systematically evaluate, and clinically test an integrated cessation intervention comprised of a depression-specific behavioral activation (ba) for cessation mobile app ("goal2quit") packaged with nicotine replacement therapy (nrt) sampling. this integrated intervention will address the need for an easily disseminable, evidence-based, depression-specific cessation intervention for delivery via primary care.


Eligibility criteria:
inclusion criteria: * current elevated depressive symptoms defined as a score of \> 10 (at least mild depression) on the patient health questionnaire-8 (phq-8) * current smoking, defined as smoking 10+ cigarettes/day, for 25+ days out of the last 30, for the last 6+ months * ownership of an android or ios smartphone * age 18+ * possess a valid e-mail address that is checked daily to access follow-up assessments * english fluency exclusion criteria: - contraindications for nrt (pregnancy/intention to become pregnant/breastfeeding, recent cardiovascular trauma/uncontrolled hypertension) - severe visual impairment, which may limit ability to utilize an app
efficacy of bioptron light therapy (blt) on post chemotherapy oral mucositis

Conditions: Oral Mucositis (Ulcerative)

Summary: the study aimed to study the effect of bioptron light therapy (blt) on oral mucositis after receiving chemotherapy in patients with head and neck cancer,oral mucositis (om) is a common and severe acute side-effect of many oncologic treatments, especially in patients treated for head and neck cancer. it affects quality of life and require supportive care and proper treatment plane. this study had been conducted on thirty cancer patients (head \&neck) receiving chemotherapy \& radiotherapy (males and females) with oral mucositis with ulceration and pain(grade 2 and more), their age ranged from 35 to 55 years, capable of understanding the study assessment method and willing to complete the current study, they were free from any immunodeficiency disorders or diseases that could impair the healing process and impact the results as diabetes mellitus. patients were randomly allocated from patients from the national cancer institute, cairo university. group a (blt group): this group consisted of 15 patients receiving blt for about 10 minutes every day for thirty days in addition to routine oral mucositis medical care (analgesics, anti-inflammatory treatment and antimicrobial treatment for any new mouth infections), group b (control group): this group consisted of 15 patients receiving daily routine oral mucositis medical care(analgesics, anti-inflammatory treatment and antimicrobial treatment for any new mouth infections) for thirty days the methods of evaluation in the current study were the who oral mucositis scale (oms) and the common toxicity criteria scale (ctcs). at the same time, the treatment equipment was the polarized light therapy device bioptron compact iii (pag-860 manufactured in switzerland) assessment by who oral mucositis scale and (oms) and (ctcs) were used before treatment and after treatment to measure improvement in oral mucositis. the results of who oral mucositis scale (oms) and the common toxicity criteria scale (ctcs) were assessed first at the beginning of the study and one month after the end of the study; calculation of mean, standard deviation, minimum and maximum for each group was done by descriptive statistics, means comparison between the two groups pre and post-application and within each group was made using the t-test. with a level of significance alpha point of 0.05


Eligibility criteria:
inclusion criteria: * cancer patients (head \&neck) receiving chemotherapy \& radiotherapy * males and females * age ranged from 35-55 years * all patients capable of understanding the study assessment method and willing to complete the current study * patients free from any immunodeficiency disorders or diseases that could impair the healing process and impact the results as diabetes . exclusion criteria: * patients suffering from immunodeficiency disorders or diseases that could impair the healing process and impact the results as diabetes . * cognitive impairment
a phase i comparative blinded trial of several hiv-1 derived immunogens in infected individuals with >= 500 cd4 cells/mm3

Conditions: HIV Infections

Summary: primary: to compare the immunogenicity and safety of each of several hiv-1 derived immunogens versus control in hiv-infected individuals with cd4 counts greater than or equal to 500 cells/mm3. secondary: to determine whether significant advantages to any one vaccine exist. before large clinical trials of anti-hiv vaccines are undertaken, it is important to determine whether there are significant advantages to any one of the vaccines currently offered for such studies.

before large clinical trials of anti-hiv vaccines are undertaken, it is important to determine whether there are significant advantages to any one of the vaccines currently offered for such studies. patients are randomized to receive one of four vaccines or one of two placebo controls. the vaccines are: rgp 120/hiv-1iiib, rgp 120/hiv-1mn, rgp 120/hiv-1sf, and env 2-3. the two control immunogens are aluminum hydroxide (alum) and biocine placebo vaccine 2 (mf-59 adjuvant emulsion in citrate buffer). patients are vaccinated at weeks 0, 4, 8, 12, 16, 20, 28, and 36. if significant benefit is seen among vaccine patients, then placebo patients may receive vaccination with one of the immunogens producing an immune response.

Eligibility criteria:
inclusion criteria concurrent medication: allowed: * short-term nonsteroidal anti-inflammatory therapy. patients must have: * hiv seropositivity. * cd4 count \>= 500 cells/mm3. * successful establishment of ebv-transformed b-cell lines at study entry. * consent of parent or guardian if \< 18 years of age. exclusion criteria co-existing condition: patients with the following symptoms or conditions are excluded: * suspected or known allergies to any vaccine components. * medical contraindication. * problem with compliance. concurrent medication: excluded: * antiretroviral therapy (e.g., azt, ddi, or ddc). * agents with putative immunomodulating activity (e.g., interferon, steroids, hematopoietin). * parenteral therapies (including sc allergy sensitization). * other investigational hiv drugs or therapies. prior medication: excluded: * any prior vaccinations against hiv. * antiretroviral therapy (e.g., azt, ddi, or ddc) within the past 6 months. * agents with putative immunomodulating activity (e.g., interferon, steroids, hematopoietin) within the past 3 months. * parenteral therapies (including sc allergy sensitization) within the past 3 months. * other investigational hiv drugs or therapies within the past 3 months.

Keywords: vaccines, synthetic hiv-1 adjuvants, immunologic aids-related complex hiv envelope protein gp120 aids vaccines hiv therapeutic vaccine
3r rehabilitation management of covid-19 survivors

Conditions: Covid19

Summary: it is to explore the temporal relationships between physical fitness, cognitive, psychosocial functions, and health-related quality of life (hrqol) in covid-19 survivors over the first 15 months; and to determine the effects of centre-based (cbr), online-based cardiopulmonary rehabilitation (obr), and combined centre- and online-based rehabilitation (cobr) on survivors with initially suboptimal pulmonary functions.


Eligibility criteria:
inclusion criteria: * covid survivor at hospital discharge or 6-month post-disease onset * medically stable with an abbreviated mental test (amt) scores of \> 6 out of 10 exclusion criteria: * having contraindications to exercise * physical activity readiness questionnaire (par-q) reveals unsafety * cannot understand cantonese